The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.
Three Biomarkers Can Predict Long-Term Disease Control in Elderly Patients With MM
May 25th 2019Spanish researchers have identified 3 biomarkers, including minimal residual disease negativity, that can help define those elderly patients with multiple myeloma (MM) who are likely to achieve long-term disease control.
Read More
Feyi Olopade Ayodele on the Importance of Early Cancer Detection in a Value-Based Care System
May 17th 2019With CancerIQ, we’re really going to be helping push population health into the oncology arena where we can hopefully predict and preempt this very costly and devastating disease well in advance, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Watch
NGS Tests Gain Further Coverage in the Market
May 16th 2019In oncology, precision medicine is already well established with targeted therapies approved based on the patient’s genetic makeup or genetic variants of their tumor, and using precision medicine successfully means also using diagnostics and next-generation sequencing (NGS). Last year, CMS finalized coverage of NGS tests, which are to be used to identify patients that may benefit the most from approved treatments. And it looks like other payers may be following CMS’ lead.
Read More
Dr Howard Burris Discusses Simultaneous Approvals of Novel Therapies, Diagnostics
May 6th 2019With a biomarker attached, the odds of a drug being approved goes up from about 10% to greater than 25%, explained Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute.
Watch
New Innovations and Cures Require Overhauling Insurance and Benefit Design
May 5th 2019Healthcare is very comfortable with treating a disease, but it’s not as good with handling cures. However, the advent of gene therapy and precision medicine means more and more expensive cures are coming down the pipeline, said panelists on the last day of Asembia’s 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas, Nevada.
Read More
Feyi Olopade Ayodele Highlights Positive Outcomes of Genetic Screening for Cancer
May 4th 2019Patients who adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan, are more likely to catch a cancer before it grows beyond 1 centimeter, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Watch
Feyi Olopade Ayodele: CancerIQ Eases Access to Genetic Screening in Community Cancer Centers
April 26th 2019CancerIQ has automated a lot of time-consuming steps to allow operationally efficient community cancer centers a way of offering genetic screening in a profitable manner, said Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Watch
Study: Oncotype DX-Guided Treatment May Cut Breast Cancer Care Costs by $50 Million in US
April 26th 2019Working from findings in the landmark TAILORx study, reseachers estimated that Oncotype DX-guided treatment could reduce the total first-year breast cancer care by nearly $50 million across the United States.
Read More
Dr Howard Burris on Determining Which Patients Will Benefit From Next-Generation Sequencing
April 24th 2019Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute, discusses differentiating which patients will benefit from next-generation sequencing (NGS) and the role of NGS testing for matching patients to clinical trials.
Watch
As DTC Genetic Testing Grows Among Consumers, Insurers Are Beginning to Get on Board
April 22nd 2019It's estimated that by 2021, 100 million people will have used a direct-to-consumer (DTC) genetic test. As these tests continue to gain popularity, there is a need for educating consumers on their DTC testing results and validating these results with confirmatory testing in a medical-grade laboratory.
Read More
ctDNA Can Detect MRD and Early Cancer Recurrence in Colorectal Cancer
April 19th 2019Circulating tumor DNA (ctDNA) can be analyzed in patients with cancer to detect minimal residual disease (MRD). Two abstracts, presented at the American Association for Cancer Research Annual Meeting 2019, evaluated ctDNA analysis and ways of tracking MRD.
Read More
Harvard Team Designs Algorithm for HRD, May Find More Patients Eligible for PARP Inhibitors
April 17th 2019The scientists used machine learning to test the algorithm and believe it could double the number of women who would be treated with poly (ADP-ribose) polymerase (PARP) inhibitors for breast cancer.
Read More
Pioneers and Progress in Personalized Lung Cancer Treatment
April 12th 2019The treatment of lung cancer with personalized medicine has come a long way in recent decades, but still more achievements remain to be seen, said Bruce Johnson, MD, FASCO, immediate past president of the American Society of Clinical Oncology, during his keynote speech opening the Business of Oncology Summit hosted by the Florida Society of Clinical Oncology in Kissimmee, Florida.
Read More
NGS Identifies Survival, Treatment Outcomes for Patients With CRC Genetic Mutations
April 7th 2019Genetic alternations in colorectal cancer (CRC) are linked to different survival and treatment outcomes, according to a study that used next-generation sequencing (NGS) of tumor DNA. The study was published in Journal of Clinical Oncology.
Read More
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 6th 2019Healthcare experts may agree the shift from volume to value is well under way, but the definition of value has many answers, according to pharmaceutical company representatives discussing the issue at the 2019 Community Oncology Conference in Orlando, Florida.
Read More
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 5th 2019Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute, discusses what's needed from a policy perspective to ensure access to next-generation sequencing (NGS) tests.
Watch
Value-Based Care Is Changing Cancer Treatment Decisions as Drug Costs Continue to Rise
March 31st 2019As novel therapies drive up the cost of drugs, it is becoming increasingly difficult for community oncologists to keep costs below value-based care program targets, according to a new survey from Integra Connect.
Read More
Predicting Responders to ICB Therapy in Advanced Melanoma
March 29th 2019Recent work looking at the response to immune checkpoint blockade (ICB) therapy given before surgery for advanced melanoma found increased infiltration of B cells, a type of white blood cell, in patients who responded to therapy compared with those who did not.
Read More
Racially Diverse Cell Lines Needed for Precision Medicine to Reach Underrepresented Populations
March 27th 2019A lack of diversity in cell lines used for laboratory studies means underrepresented populations and minorities might not benefit from precision medicines as quickly as people from European ancestry.
Read More
NCCN Ovarian Cancer Guidelines Add Options for PARP Inhibitors, Bevacizumab
March 25th 2019A presentation Saturday at the National Comprehensive Cancer Network Annual Conference in Orlando, Florida, outlined several key updates for treatment in ovarian cancer based on new studies and approvals for poly (ADP-ribose) polymerase (PARP) inhibitors and bevacizumab.
Read More
Dr John Ward on Conversations With Patients After Multigene Testing
March 22nd 2019Multigene testing provides a lot of information that providers have to be familiar with in order to adequately explain it to their patients, said John H. Ward, MD, Huntsman Cancer Institute at the University of Utah.
Watch